Rezolute to Participate in Upcoming Virtual Healthcare Conferences
07 sept. 2021 16h05 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
10 août 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
03 août 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute Added to Russell Microcap® Index
28 juin 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
27 mai 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to...
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
20 mai 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
18 mai 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose...
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
17 mai 2021 16h05 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
17 mai 2021 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose...
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
27 juil. 2020 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, California, July 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in...